|1.||Hill, Adrian V S: 12 articles (09/2015 - 01/2002)|
|2.||Hoffman, Stephen L: 7 articles (12/2015 - 01/2004)|
|3.||Marsh, Kevin: 6 articles (01/2015 - 05/2006)|
|4.||Gilbert, Sarah C: 6 articles (07/2013 - 02/2005)|
|5.||Sauerwein, Robert W: 5 articles (12/2015 - 08/2004)|
|6.||Chilengi, Roma: 5 articles (01/2015 - 12/2007)|
|7.||Doumbo, Ogobara K: 5 articles (01/2015 - 12/2002)|
|8.||Moorthy, Vasee S: 5 articles (01/2013 - 01/2011)|
|9.||Richie, Thomas L: 4 articles (12/2015 - 08/2012)|
|10.||Draper, Simon J: 4 articles (01/2015 - 12/2012)|
10/01/2007 - "There is good rationale to support the development of blood-stage malaria vaccines, the most promising being the demonstration that nonimmune volunteers repeatedly challenged and cured with blood-stage parasites developed immunity to subsequent challenge as well as the demonstration of the efficacy of the first asexual blood-stage vaccine tested in a malaria endemic area (combination B) to reduce parasite density in children. "
09/01/2007 - "The primary factors contributing to the resurgence of malaria are the appearance of drug-resistant strains of the parasite, the spread of insecticide-resistant strains of the mosquito and the lack of licensed malaria vaccines of proven efficacy. "
01/01/2014 - "The opsonic phagocytosis assay appears to be a strong correlate of protection against malaria, a valuable biomarker of immunity, and provides a much-needed new tool for assessing responses to blood-stage malaria vaccines and measuring immunity in populations."
01/01/2012 - "This first vaccine against a human parasite is a groundbreaking achievement, but improved malaria vaccines conferring higher protection will be needed if the aspiration of malaria eradication is to be achieved."
01/01/1990 - "It is likely that a greater understanding of the basic biology of malaria parasite-host relationships will lead to development of improved malarial vaccines."
01/01/2011 - "Considering that the recently generated anti-malaria vaccines induce only partial protection against infection, it is encouraging that, at least in mouse models, immunity is not negatively affected by subsequent exposure and infection with the parasite."
10/01/2006 - "Furthermore, the implications of helminth infection for the efficacy of malaria vaccines will be discussed."
01/13/2005 - "Liver stages of the parasite are a prime target for malaria vaccines because they can be completely eliminated by sterilizing immune responses, thereby preventing malarial infection. "
08/21/2004 - "This technique will allow studying Th1 and Th2 cytokine patterns elicited in response to infection for prospectively evaluating the efficacy of malarial vaccines."
11/01/2013 - "These data suggest that malaria vaccines mimicking naturally acquired immunity should ideally induce antibody responses that can be boosted by natural infections."
|3.||Falciparum Malaria (Plasmodium falciparum Malaria)
10/15/1988 - "This immunologic defect may partially explain the difficulty with which natural immunity to falciparum malaria develops and may have important implications for the efficacy of potential malaria vaccines in endemic areas. "
02/18/2013 - "Our results provide important implications for developing effective malaria vaccines and better understanding of acquired immunity against falciparum malaria."
08/01/2006 - "Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview."
12/01/2002 - "Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali."
01/01/2002 - "Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria."
|4.||Bites and Stings (Sting)
01/01/2011 - "As an alternative to these Phase IIb field trials, the efficacy of candidate malaria vaccines can first be assessed through the deliberate exposure of participants to the bites of infectious mosquitoes (sporozoite challenge) or to an inoculum of blood-stage parasites (blood-stage challenge). "
01/01/2014 - "To better assess malaria vaccines in rhesus, a method to challenge large numbers of monkeys by mosquito bite was developed. "
02/15/2005 - "We calculated the number and growth rate of Plasmodium falciparum parasites emerging in recipients of candidate preerythrocytic malaria vaccines and unvaccinated control subjects undergoing mosquito-bite challenge. "
01/01/2014 - "With the goal of accelerating clinical development of malaria vaccines, the outcome of infections experimentally induced in naïve and semi-immune volunteers by infected mosquito bites was compared. "
12/01/2012 - "ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans."
|2.||Merozoite Surface Protein 1 (MSA1)
|3.||1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)
|4.||Biological Markers (Surrogate Marker)
|5.||Antimalarials (Antimalarial Agents)
|6.||Japanese Encephalitis Vaccines
|8.||Synthetic Vaccines (Recombinant Vaccines)
|9.||Complement System Proteins (Complement)